On December 1, 2023 Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, reported that it will hold its Analyst Day focused on its R&D portfolio and strategy on Tuesday, December 5, 2023 in New York (Press release, Neurocrine Biosciences, DEC 1, 2023, View Source [SID1234638093]). The event will be held in-person and via webcast. It will feature Kevin Gorman, Chief Executive Officer, and Jude Onyia, Chief Scientific Officer, as well as additional members of Neurocrine Biosciences’ management team who will facilitate a panel discussion on the burden of congenital adrenal hyperplasia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event schedule and Zoom webcast information is as follows:

Analyst Day Event: 1:00 p.m. – 3:45 p.m. Eastern Time
Zoom Webinar ID: 831 1056 0450
Zoom Passcode: 536894
A live video webcast of the event will begin at 1:00 p.m. Eastern Time and can be accessed on Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month. Upon the conclusion of the webcast event, in-person attendees will be welcome to attend breakout sessions ending at 5:00 p.m. Eastern Time.